Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 523-531

  Ekblad, Lars ^a   Kjellström, Johan ^a   Johnsson, Anders ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

ABCB1; Cisplatin; Colon cancer; Drug resistance; MDR1; Oligonucleotide array sequence analysis; Oxaliplatin; P glycoprotein; Platinum accumulation

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER A1; CISPLATIN; COMPLEMENTARY DNA; DNA; OXALIPLATIN; PLATINUM;

ARTICLE; CANCER CELL; CELL LYSATE; COLON CANCER; CONTROLLED STUDY; CROSS RESISTANCE; CULTURE MEDIUM; CYTOTOXICITY; DNA MICROARRAY; DRUG ACCUMULATION; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; HUMANS; ORGANOPLATINUM COMPOUNDS; P-GLYCOPROTEIN; PLATINUM; RNA, MESSENGER; TOXICITY TESTS;

EID: 77951261957     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328337b867     Document Type: Article

References (22)

1. Wang D, Lippard S. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
2. Rabik C, Dolan M. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33:9-23.
3. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22:7265-7279.
4. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1:227-235.
5. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opin Drug Metab Toxicol 2007; 3:281-294.
6. Heffeter P, Jungwirth U, Jakupec M, Hartinger C, Galanski M, Elbling L, et al. Resistance against novel anticancer metal compounds: differences and similarities. Drug Resist Updat 2008; 11:1-16.
7. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007; 63:12-31.
8. Koopman M, Venderbosch S, Nagtegaal I, van Krieken J, Punt C. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer 2009; 45:1935-1949.
9. Pohl A, Lurje G, Manegold P, Lenz H. Pharmacogenomics and pharmacogenetics in colorectal cancer. Adv Drug Deliv Rev 2009; 61:375-380.
10. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 1999; 59:8-13.
11. Jönsson G, Staaf J, Olsson E, Heidenblad M, Vallon-Christersson J, Osoegawa K, et al. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2007; 46:543-558.
12. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg Å., Peterson C. BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data. Genome Biol 2002; 3: software0003.1-003.6. doi:10.1186/gb-2002-3-8-software0003.
13. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002; 30:e15.
14. Hyafil F, Vergely C, Du Vignaud P, Grand-Perret T. In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative. Cancer Res 1993; 53:4595-4602.
15. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 2002; 5:147-161.
16. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001; 48:398-406.
17. Gourdier I, Del Rio M, Crabbé L, Candeil L, Copois V, Ychou M, et al. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. FEBS Lett 2002; 529:232-236.
18. Stordal B, Pavlakis N, Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 2007; 33:347-357.
19. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 1997; 57:850-856.
20. Siddik ZH, Mims B, Lozano G, Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res 1998; 58:698-703.
21. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005; 53:13-23.
22. Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008; 73:592-604.